Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: review decision - November 2014 information

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: appendix A - GE decision paper - October 2014

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: appendix A - GE decision paper - October 2014 (PDF 290 KB)

Review Proposal - June 2014 information

Appendix A - provisional matrix of stakeholders

Appendix A - provisional matrix of stakeholders (PDF 103 KB)

Appendix B - addendum to the review considerations for TA158 and TA168

Appendix B - addendum to the review considerations for TA158 and TA168 (PDF 146 KB)

Appendix C - consultee and commentator comments on TA168 proposal

Appendix C - consultee and commentator comments on TA168 proposal (PDF 102 KB)

Review decision - November 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 79 KB)

Review Proposal - September 2011 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 68 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination information

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination (PDF 126 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 82 KB)

Consultee and commentator comments on the ACD

Manufacturer/sponsor: GlaxoSmithKline

Manufacturer/sponsor: GlaxoSmithKline (PDF 11 KB)

Manufacturer/sponsor: Roche

Manufacturer/sponsor: Roche (PDF 89 KB)

Professional and patient groups: British Thoracic Society

Professional and patient groups: British Thoracic Society (PDF 15 KB)

Professional and patient groups: Diabetes UK

Professional and patient groups: Diabetes UK (PDF 40 KB)

Professional and patient groups: General Practice Airways Group

Professional and patient groups: General Practice Airways Group (PDF 41 KB)

Professional and patient groups: Health Protection Agency

Professional and patient groups: Health Protection Agency (PDF 23 KB)

Professional and patient groups: Royal College of Paediatrics and Child Health

Professional and patient groups: Royal College of Paediatrics and Child Health (PDF 62 KB)

Professional and patient groups: Royal College of Physicians

Professional and patient groups: Royal College of Physicians (PDF 11 KB)

Professional and patient groups: Royal College of Nursing

Professional and patient groups: Royal College of Nursing (PDF 20 KB)

Others: Department of Health

Others: Department of Health (PDF 11 KB)

Others: NHS Quality Improvement Scotland

Others: NHS Quality Improvement Scotland (PDF 20 KB)

Others: Welsh Assembly Government

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: appraisal consultation

Influenza (prophylaxis) - amantidine, oseltamivir and zanamivir: appraisal consultation document information

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: evaluation report

Evaluation report: overview

Evaluation report: overview (PDF 85 KB)

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: assessment report

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: assessment report (PDF 1.31 MB)

Consultee and commentator comments on the assessment report

Consultee and commentator comments on the assessment report: British Thoracic Society

Consultee and commentator comments on the assessment report: British Thoracic Society (PDF 18 KB)

Consultee and commentator comments on the assessment report: Diabetes UK

Consultee and commentator comments on the assessment report: Diabetes UK (PDF 45 KB)

Consultee and commentator comments on the assessment report: GlaxoSmithKline

Consultee and commentator comments on the assessment report: GlaxoSmithKline (PDF 27 KB)

Consultee and commentator comments on the assessment report: Roche

Consultee and commentator comments on the assessment report: Roche (PDF 98 KB)

Consultee and commentator comments on the assessment report: Royal College of Nursing

Consultee and commentator comments on the assessment report: Royal College of Nursing (PDF 13 KB)

Consultee and commentator comments on the assessment report: Royal College of Physicians

Consultee and commentator comments on the assessment report: Royal College of Physicians (PDF 14 KB)

Non-manufacturer submissions

Non-manufacturer submissions: British Thoracic Society

Non-manufacturer submissions: British Thoracic Society (PDF 55 KB)

Non-manufacturer submissions: Diabetes UK

Non-manufacturer submissions: Diabetes UK (PDF 61 KB)

Non-manufacturer submissions: Health Protection Agency

Non-manufacturer submissions: Health Protection Agency (PDF 76 KB)

Non-manufacturer submissions: Royal College of Nursing

Non-manufacturer submissions: Royal College of Nursing (PDF 14 KB)

Non-manufacturer submissions: Royal College of Physicians

Non-manufacturer submissions: Royal College of Physicians (PDF 42 KB)

Manufacturer submissions (executive summary only)

Manufacturer submissions (executive summary only): Roche

Manufacturer submissions (executive summary only): Roche (PDF 556 KB)

Manufacturer submissions (executive summary only): GlaxoSmithKline

Manufacturer submissions (executive summary only): GlaxoSmithKline (PDF 159 KB)

Manufacturer submissions (executive summary only): Alliance Pharmaceuticals

Manufacturer submissions (executive summary only): Alliance Pharmaceuticals (PDF 14 KB)

Expert written personal statements

Expert written personal statements: Fleming

Expert written personal statements: Fleming (PDF 141 KB)

Expert written personal statements: Gunaratnam

Expert written personal statements: Gunaratnam (PDF 31 KB)

Expert written personal statements: Watson

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: provisional matrix of consultees and commentators

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: draft scope